Boston Scientific Short-term debt and current portion of long-term debt decreased by 38.1% to $299.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 83.2%, from $1.78B to $299.00M. Over 5 years (FY 2020 to FY 2025), Short-term debt and current portion of long-term debt shows an upward trend with a 87.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase may signal higher refinancing risk or a shift in capital structure, while a decrease indicates debt reduction or successful long-term refinancing.
This represents the portion of total debt obligations, including bank loans, commercial paper, and the current portion o...
Standard debt metric; peers report this as current portion of long-term debt or short-term borrowings.
other_debt_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $262.00M | $261.00M | $261.00M | $238.00M | $170.00M | $20.00M | $20.00M | $510.00M | $559.00M | $513.00M | $531.00M | $1.09B | $1.58B | $1.65B | $1.78B | $777.00M | $480.00M | $483.00M | $299.00M |
| QoQ Change | — | -0.4% | +0.0% | -8.8% | -28.6% | -88.2% | +0.0% | >999% | +9.6% | -8.2% | +3.5% | +104.3% | +45.6% | +4.6% | +7.6% | -56.3% | -38.2% | +0.6% | -38.1% |
| YoY Change | — | — | — | — | -35.1% | -92.3% | -92.3% | +114.3% | +228.8% | >999% | >999% | +112.7% | +182.6% | +222.0% | +234.8% | -28.4% | -69.6% | -70.8% | -83.2% |